D
Delvys Rodriguez-Abreu
Researcher at University of Las Palmas de Gran Canaria
Publications - 159
Citations - 27672
Delvys Rodriguez-Abreu is an academic researcher from University of Las Palmas de Gran Canaria. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 33, co-authored 122 publications receiving 19004 citations. Previous affiliations of Delvys Rodriguez-Abreu include Hospital Universitario Insular de Gran Canaria.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
TL;DR: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski,Robert M. Jotte,Federico Cappuzzo,Francisco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Claudia Kelsch,Anthony Lee,Shelley Coleman,Yu Deng,Yijing Shen,Marcin Kowanetz,Ariel Lopez-Chavez,Alan Sandler,Martin Reck +19 more
TL;DR: The addition of atezolizumab to bevacIZumab plus chemotherapy significantly improved progression‐free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD‐L1 expression and EGFR or ALK genetic alteration status.
Journal ArticleDOI
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone,Martin Reck,Luis Paz-Ares,Benjamin C. Creelan,Leora Horn,Martin Steins,Enriqueta Felip,Michel M. van den Heuvel,Tudor-Eliade Ciuleanu,Firas Benyamine Badin,Neal Ready,T. Jeroen N. Hiltermann,Suresh G. Nair Md,Rosalyn A. Juergens,Solange Peters,Elisa Minenza,John Wrangle,Delvys Rodriguez-Abreu,Hossein Borghaei,George R. Blumenschein,Liza C. Villaruz,Libor Havel,Jana Krejci,Jesus Corral Jaime,Han Chang,William J. Geese,Prabhu Bhagavatheeswaran,Allen C. Chen,Mark A. Socinski +28 more
TL;DR: Nivolumab was not associated with significantly longer progression‐free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD‐L1 expression level of 5% or more.